Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Kennedy spotlights West Nile virus: Pathogen inactivation technology deemed "promising" in written remarks from Sen. Edward Kennedy (D-Mass.) to FDA commissioner-nominee Mark McClellan, MD/PhD. "Should it be a priority for FDA to evaluate this exciting new technology?" Kennedy asks. "Pathogen inactivation may prove valuable as an approach to reducing risk in blood products," McClellan replies. "These approaches, however, must be carefully evaluated for their immediate and long-term safety," he cautions...

You may also be interested in...



CBER Reorganization Poses “Significant” Staff Retention Issues – Zoon

The reorganization of FDA's Center for Biologics Evaluation & Research poses a significant problem for employee retention, Director Kathryn Zoon told the FDA Science Board Oct. 25

CBER Reorganization Poses “Significant” Staff Retention Issues – Zoon

The reorganization of FDA's Center for Biologics Evaluation & Research poses a significant problem for employee retention, Director Kathryn Zoon told the FDA Science Board Oct. 25

West Nile Virus Nucleic Acid Firms Will Hear Regulatory Guidance Nov. 4-5

Blood banks expect to begin screening donated blood for the West Nile Virus using nucleic acid tests (NAT) by mid-2003 under an IND exemption

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel